Présentation de l'entreprise
Aimei Health Technology Co., Ltd operates within the financial services sector, specifically categorized under the industry of shell companies, a designation that implies the entity currently lacks significant operational activities and is primarily structured for potential business combinations. The company's business model centers on the intention to execute a merger, share exchange, asset acquisition, stock purchase, or reorganization with one or more other businesses, alongside plans to acquire small-cap entities in the biopharmaceutical sector. According to available financial data, the company holds a market capitalization of $171.41M, while its annual revenue and employee count are not available for disclosure in current reports. The substantial market capitalization relative to the absence of reported revenue and employee figures suggests a valuation driven primarily by speculative potential for future corporate transactions rather than established operational earnings or workforce scale.
Santé financière
The financial statements report a net income of $1.41M for the trailing twelve months, while revenue and EBITDA figures are not available, creating a scenario where the gap between revenue and net income cannot be analyzed to determine the traditional cost structure. The company generates free cash flow amounting to $269,617, which provides a measure of financial flexibility despite the lack of reported operating revenue. Analysis of the margin structure reveals that the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, indicating that reported earnings do not correspond to standard revenue generation metrics typically seen in operational businesses. In terms of leverage, the company holds cash of $2,979 against a total debt obligation of $1.66M, and the debt-to-equity ratio is not available, suggesting a balance sheet that is heavily weighted towards liabilities relative to minimal liquid assets. Liquidity is severely constrained, as evidenced by a current ratio of 0.01, which indicates an inability to cover short-term liabilities with short-term assets. Furthermore, the return on equity is not available, while the return on assets stands at -1.0%, revealing that the company's assets are currently generating negative returns and undermining management effectiveness.
Évaluation de la valorisation
The trailing twelve-month price-to-earnings ratio is recorded at 140.00, whereas the forward price-to-earnings ratio is not available, implying that the market currently prices in significant uncertainty regarding future earnings trajectories. The price-to-book ratio is listed at -49.82, a negative figure that indicates the stock is trading below its book value, which often occurs when liabilities exceed assets or when the market assigns no value to the entity's tangible net worth. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not available, preventing a direct comparison of the company's valuation relative to its sales or enterprise earnings power. The stock has exhibited significant price volatility over the past year, trading between a 52-week high of $130.37 and a 52-week low of $6.75. Without the current share price, the exact position relative to the range cannot be calculated, but the wide spread between the high and low demonstrates extreme price instability. The beta value is -1.50, a negative coefficient that suggests the stock's price movements are inversely correlated with the broader market, moving opposite to market trends with high sensitivity.
Growth & Income
Revenue growth year-over-year is not available, and earnings growth year-over-year is recorded at -30.2%, indicating a sharp contraction in profitability relative to the prior period when data exists. Since the revenue growth figure is unavailable, a direct comparison of earnings growth speed versus revenue growth cannot be performed, but the negative earnings growth highlights a deterioration in financial performance. The company does not pay dividends, as the dividend yield is not available and the payout ratio is 0.0%, meaning the entity retains all reported earnings rather than distributing them to shareholders. Consequently, the overall growth and income profile is characterized by negative earnings growth, a lack of dividend distribution, and a reliance on speculative valuation metrics rather than consistent cash generation or income yields.